

Date: 14th May, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Injectable Facility (F-III) located at Karakhadi

Ref.: Our earlier intimation dated 18th February 2026 - USFDA inspection at Alembic Pharmaceuticals Limited' Injectable Facility (F-III) located at Karakhadi

We would like to inform the exchange that the Company has received an Establishment Inspection Report (EIR) from the USFDA, for its Injectable facility (F-III) located at Karakhadi on 13th May, 2026. The USFDA inspection was conducted from 9th February 2026 to 18th February, 2026.

We request you to kindly take the same on record.

Thank you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary